Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.34
+2.3%
$1.22
$1.05
$10.16
$41.08M1.64268,576 shs370,202 shs
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.77
+5.4%
$1.85
$0.89
$3.19
$50.31M0.12295,516 shs139,139 shs
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
$0.39
$0.26
$1.16
$10.78M0.1997,242 shs173,100 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$1.20
-4.0%
$0.58
$0.33
$1.53
$117.86M1.07706,967 shs2.49 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
+2.29%+3.88%+4.69%-12.42%-81.21%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
+5.36%+8.26%-7.33%+12.03%+50.00%
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
0.00%0.00%0.00%0.00%0.00%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-4.00%+52.38%+169.78%+139.95%+16.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
2.6133 of 5 stars
3.52.00.00.01.13.30.6
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.8175 of 5 stars
3.65.00.00.01.90.00.6
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.0422 of 5 stars
3.43.00.00.03.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.00
Buy$17.711,221.96% Upside
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3.17
Buy$8.20363.28% Upside
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
0.00
N/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.75
Moderate Buy$4.33261.11% Upside

Current Analyst Ratings Breakdown

Latest NHWK, ACRV, GANX, and ONCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/21/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/19/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/16/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/16/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/15/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
5/5/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$6.00
5/4/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$50K1,060.23N/AN/A$0.28 per share6.32
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
$6.38M0.00N/AN/A$2.82 per share0.00
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A$0.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%N/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%7/30/2025 (Estimated)

Latest NHWK, ACRV, GANX, and ONCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.10N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.16-$0.16N/A-$0.16$0.03 millionN/A
5/14/2025Q1 2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.09-$0.06+$0.03-$0.06N/AN/A
5/13/2025Q1 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57-$0.51+$0.06-$0.51N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/A
11.17
11.17
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.05
2.22
2.22
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
0.27
0.99
0.99
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
3.20
3.20

Institutional Ownership

CompanyInstitutional Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
71.62%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
21.16%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%

Insider Ownership

CompanyInsider Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
11.90%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
7.18%
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
15.90%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
0.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
5831.35 million27.62 millionNot Optionable
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2029.95 million27.80 millionOptionable
NightHawk Biosciences, Inc. stock logo
NHWK
NightHawk Biosciences
7726.08 million21.94 millionOptionable
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3094.28 million94.19 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acrivon Therapeutics stock logo

Acrivon Therapeutics NASDAQ:ACRV

$1.34 +0.03 (+2.29%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.38 +0.04 (+3.06%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.77 +0.09 (+5.36%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.78 +0.00 (+0.28%)
As of 07/9/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

NightHawk Biosciences stock logo

NightHawk Biosciences NYSE:NHWK

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$1.20 -0.05 (-4.00%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.19 -0.01 (-0.83%)
As of 04:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.